Sutro Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sutro Biopharma, Inc. (Nasdaq: STRO) on June 2, 2025. The filing discloses the appointment of a new Chief Financial Officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes
On June 2, 2025, the Company appointed Gregory K. Chow as Chief Financial Officer, principal financial officer, and principal accounting officer. Mr. Chow replaces the prior leadership in this role effective immediately.
Compensation and Severance Terms
- Base Salary: $475,000 annually.
- Cash Bonus: Target annual opportunity of 40% of base salary.
- Equity Awards:
- Option to purchase 275,000 shares of common stock, vesting over four years (25% on the one-year anniversary, then monthly).
- Grant of 100,000 restricted stock units (RSUs), vesting in four equal annual installments.
- Severance (Termination without Cause/Good Reason):
- 15 months of base salary paid in monthly installments.
- Pro rata bonus based on actual achievement.
- COBRA premiums for up to 15 months.
- Accelerated vesting of time-based equity awards vesting within 15 months.
- Severance (Change in Control within 18 months):
- 15 months of base salary paid in a lump sum.
- Pro rata target bonus paid in a lump sum.
- Additional cash severance equal to 125% of the target bonus.
- COBRA premiums for up to 15 months.
- Full accelerated vesting of all outstanding stock options and RSUs.
Investor Verification Checklist
- Verify the full text of the Offer Letter and Severance Plan, which are referenced but not included in this filing.
- Confirm the impact of the new CFO appointment on the Company's financial reporting and strategic direction.
- Review the Company's upcoming Form 10-Q for the quarter ending June 30, 2025, where the Offer Letter will be filed as an exhibit.
- Assess the Company's cash burn rate relative to the new executive compensation obligations.